BASE extracts a variety of biomarker classes from proprietary database.
The database includes multiple types of molecular biomarkers (e.g., mutational patterns, CNVs beyond coding regions, somatic structural variations, gene expression).
MNM’s extensive tumor database allows for selection of a cohort of responders to a given therapy. Then, ”Biomarker Signature” is defined as a consensus biomarker set allowing to predict the response for new patients. Proprietary AI is used to optimize the biomarker signature.